Median number of DCs administered per patient | |||||||
no. x 106 | (range) | ||||||
DC/PC3 | Selected | 28.15 | (23.17-37.10) | ||||
Adherence | 30.73 | (25.90-31.84) | |||||
p-value | >0.99 | ||||||
DC/PC3-M1 | Selected | 28.86 | (20.49-33.85) | ||||
Adherence | 26.75 | (24.80-34.05) | |||||
p-value | 0.80 | ||||||
Phenotype of DCs administered (median) | |||||||
CD14+ (%) | (range) | CD83+ (%) | (range) | PI+ (%) | (range) | ||
DC/PC3 | Selected | 2.76 | (1.85-5.71) | 96.18 | (86.35-98.46) | 7.94 | (4.36-18.06) |
Adherence | 1.09 | (0.82-4.41) | 97.70 | (90.70-98.40) | 8.99 | (4.81-11.50) | |
p-value | 0.23 | >.99 | 0.87 | ||||
DC/PC3-M1 | Selected | 3.45 | (1.15-7.9) | 95.60 | (85.67-98.49) | 12.52 | (4.34-17.09) |
Adherence | 2.04 | (1.29-6.4) | 98.20 | (96.80-98.90) | 10.10 | (5.83-12.60) | |
p-value | 0.87 | 0.12 | 0.72 | ||||
Median number of DC/KLH administered per patient in all three studies | |||||||
no. x 106 | (range) | ||||||
Selected | 9.04 | (5.06-17.41) | |||||
Adherence | 9.86 | (4.69-16.31) | |||||
p-value | 0.59 | ||||||
Phenotype of DC/KLH administered in all three studies (median) | |||||||
CD14+ (%) | (range) | CD83+ (%) | (range) | PI+ (%) | (range) | ||
Selected | 0.64 | (0.01-2.00) | 96.79 | (92.35-99.30) | 1.85 | (0.92-9.30) | |
Adherence | 0.36 | (0-2.82) | 95.69 | (86.00-99.97) | 1.27 | (0.34-12.19) | |
p-value | 0.24 | 0.55 | 0.10 |